These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26763088)

  • 1. Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Iremashvili V; Barney SL; Manoharan M; Kava BR; Parekh DJ; Punnen S
    Int J Urol; 2016 Apr; 23(4):313-7. PubMed ID: 26763088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is It Time to Revisit the Role of Prostate-specific Antigen Kinetics in Active Surveillance for Prostate Cancer?
    Iremashvili V; Kava BR; Manoharan M; Parekh DJ; Punnen S
    Urology; 2016 Sep; 95():139-44. PubMed ID: 27130265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
    Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
    J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling prostate specific antigen kinetics in patients on active surveillance.
    Zhang L; Loblaw A; Klotz L
    J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
    J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
    Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
    Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
    Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
    BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial Comment to Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.
    Mitsuzuka K
    Int J Urol; 2016 Apr; 23(4):317-8. PubMed ID: 26840383
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
    Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
    Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
    J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
    Ross AE; Loeb S; Landis P; Partin AW; Epstein JI; Kettermann A; Feng Z; Carter HB; Walsh PC
    J Clin Oncol; 2010 Jun; 28(17):2810-6. PubMed ID: 20439642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-institutional evaluation of active surveillance for low risk prostate cancer.
    Eggener SE; Mueller A; Berglund RK; Ayyathurai R; Soloway C; Soloway MS; Abouassaly R; Klein EA; Jones SJ; Zappavigna C; Goldenberg L; Scardino PT; Eastham JA; Guillonneau B
    J Urol; 2013 Jan; 189(1 Suppl):S19-25; discussion S25. PubMed ID: 23234624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
    Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
    J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.